Cargando…

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine

Detalles Bibliográficos
Autores principales:	Anastasopoulou, Eleftheria A, Tzonis, Panagiotis, Fortis, Sotirios P, Mahaira, Louisa, Vaxevanis, Christoforos, Ardavanis, Alexandros, Mittendorf, Elizabeth A, Peoples, George E, Baxevanis, Constantin N, Papamichail, Michael, Perez, Sonia A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652460/ http://dx.doi.org/10.1186/2051-1426-3-S2-P427

Ejemplares similares

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
por: Voutsas, Ioannis F., et al.
Publicado: (2016)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
por: Brown, Tommy A., et al.
Publicado: (2020)

Further insight into AE37 peptide vaccination in prostate cancer
por: Anastasopoulou, Eleftheria A, et al.
Publicado: (2017)

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
por: Fortis, Sotirios P., et al.
Publicado: (2017)

Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
por: Fortis, Sotirios P., et al.
Publicado: (2017)

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
por: Mittendorf, Elizabeth A., et al.
Publicado: (2016)

Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
por: Baxevanis, Constantin N., et al.
Publicado: (2020)

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours
por: Sotiropoulou, P A, et al.
Publicado: (2003)

Linking tumor with systemic environment in the search for novel biomarkers in breast cancer
por: Fortis, Sotirios P, et al.
Publicado: (2015)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
por: Goulielmaki, Maria, et al.
Publicado: (2023)

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells
por: Gritzapis, A D, et al.
Publicado: (2003)

Vaccination in Spain and Her Colonies
Publicado: (1870)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope
por: Sotiriadou, R, et al.
Publicado: (2001)

Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance
por: Fortis, Sotirios P., et al.
Publicado: (2022)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome
por: Stokidis, Savvas, et al.
Publicado: (2023)

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
por: O’Shea, Anne E., et al.
Publicado: (2021)

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2(+) breast cancer
por: Costa, Ricardo, et al.
Publicado: (2019)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Immune profiling of breast cancer patients: relationship between tumour antigen T cell responses with suppressor and effector leukocyte populations
por: Janssen, Nicole, et al.
Publicado: (2015)

EPH20 Does a Mother's Previous Experience with COVID-19 Infection Change Her Intention to Vaccinate Her Children
por: Zakeri, M, et al.
Publicado: (2022)

Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
por: Ruzzi, Francesca, et al.
Publicado: (2022)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity
por: Dimitriadis, Alexios, et al.
Publicado: (2009)

Are Thyroid Hormone and Tumor Cell Proliferation in Human Breast Cancers Positive for HER2 Associated?
por: Mourouzis, Iordanis, et al.
Publicado: (2015)

The thin red line between the immune system and cancer evolution
por: Baxevanis, Constantin N., et al.
Publicado: (2022)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

HER2 expression status in diverse cancers: review of results from 37,992 patients
por: Yan, Min, et al.
Publicado: (2015)

Heterogeneity in potential COVID-19 vaccine-related AEs
Publicado: (2021)

Systemic AEs common after COVID-19 vaccination
Publicado: (2022)

Acute neurological AEs after COVID-19 vaccination
Publicado: (2022)

Combination Immunotherapy in Prostate Cancer
por: Baxevanis, Constantin N., et al.
Publicado: (2022)

Novel EXO-T vaccine using polyclonal CD4(+) T cells armed with HER2-specific exosomes for HER2-positive breast cancer
por: Li, Rong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_51u2siknhgivv8etg8o3fptgpb